Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer

@article{WojtowiczPraga1996PhaseIT,
  title={Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer},
  author={Slawomir M. Wojtowicz-Praga and Jennifer A. Low and John Marshall and Elizabeth A Ness and Robert L Dickson and James Barter and Mark Sale and Peter J � McCann and J. L. Moore and Alice Cole and Michael J. Hawkins},
  journal={Investigational New Drugs},
  year={1996},
  volume={14},
  pages={193-202}
}
Degradation of basement membrane and extracellular matrix by matrix metalloproteinases (MMPs) is believed to be required for tumor invasion, tumor-induced angiogenesis and vascular invasion. A synthetic hydroxamate, batimastat (also known as BB-94), inhibits MMPs by binding the zinc ion in the active site of the MMP. Batimastat inhibits at least 50% of MMP activity at concentrations less than or equal to 10 ng/ml in vitro. Batimastat retarded ascites accumulation and increased survival in mice… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…